Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vismodegib and Radiation for Locally Advanced Head and Neck BCC
NCT01835626Phase 2
Key facts
- Status
- Completed
- Start
- May 2013
- Primary completion
- Sep 2019
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- vismodegib
- Conditions
- basal cell carcinoma (BCC)
01
Overview
Phase 2, open-label, single-arm trial of vismodegib in basal cell carcinoma (BCC). Primary endpoint: Percentage of Patients With Local-regional Control Rate at 12 months. Started May 2013; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Vismodegib and Radiation Therapy
Vismodegib induction followed by concurrent Vismodegib and Radiation
03
Who it enrols
Patients with locally advanced BCC of the head and neck, inoperable or medically contraindicated for surgery, with adequate organ function and no distant metastasis.
04
Endpoints
Primary
Percentage of Patients With Local-regional Control Rate
Secondary
Progression-Free Survival
Overall Survival
Percentage of Patients by Treatment-Related Adverse Events
Number of Patients Discontinuing Treatment Due to Toxicity
Clinical Response Rate
Percentage of Patients With a Decrease of Basal Cell Carcinoma
Beyond the preview
Go deeper on NCT01835626.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01835626.